Primary Ureteroscopy for Acute Obstructive Nephropathy Due to Ureteral Stones: A Prospective Non-randomized Feasibility and Safety Trial

Overview

Ureteroscopy (URS) is a widely used minimally invasive procedure for the management of ureteral and renal stones (1). While the procedure is generally safe and effective, patient factors such as renal function, operative time, and ASA classification may influence outcomes (2). Ureteral stones were found to be associated with deteriorated kidney function in affected patients (3). In cases of elevated urea and creatinine levels, pre-stenting of ureteroscopy was indicated (4). Limited number of studies have directly assessed the primary ureteroscopy without preoperative stenting outcomes in patients with normal versus deteriorated renal function. Understanding the impact of renal function on URS outcomes can help. A single procedure translates to reduced patient burden through fewer hospital visits, less time spent in the operating room, and a quicker return to daily activities, thus improving comfort and convenience. This approach also yields cost savings by eliminating the expenses associated with a second procedure, including hospital stays, anesthesia, and surgical supplies. Moreover, immediate stone removal via primary URS offers faster symptom relief and avoids potential stent-related complications such as pain, infection, and migration. However, the decision to forego staging must be carefully weighed against individual patient risk factors and stone complexity, as those with severe obstruction, infection, or compromised renal function may still benefit from pre-stenting to optimize procedural safety and outcomes. This study aims to evaluate whether elevated creatinine levels influence stone-free rates, complication rates, and procedural success in patients undergoing primary URS.

Interventions

• Procedure Ureteroscopy
  patients presenting with acute ureteral obstruction who undergo primary ureteroscopy (URS).

Primary outcome measures

• post operative complications [Time frame: 3 month]

Eligibility criteria

Inclusion criteria

• • Adults (>18 years) with acute unilateral ureteral obstruction confirmed by:
• Non-contrast CT (stone size ≥5mm)
• Hydronephrosis on ultrasound

• Planned for primary URS (no prior stenting/nephrostomy)
• Renal function eligibility:
• Acute deterioration (elevated serum Cr and urea) serum creatinine ≥1.3 mg/dL but less than 5 mg/dL

Exclusion criteria

• Systemic contraindications to URS:

• Uncorrected coagulopathy (INR >1.5)
• Active UTI/sepsis (requiring drainage-first approach)
• Severe cardiopulmonary compromise (ASA class ≥IV)

• Patients with hypercalcemia.
• hyperkalemia >6.5 mEq/L
• Metabolic acidosis (pH <7.1)
• Patients with pulmonary edema.
• Patients with uremic encephalopathy.
• Bilateral obstruction
• Known ureteral stricture distal to stone

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Quadruple blind

Primary purpose

Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07177313 · Acute Obstructive Nephropathy

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗